Literature DB >> 12028092

Radiation therapy following nodal surgery for melanoma: an analysis of late toxicity.

B H Burmeister1, B M Smithers, S Davis, N Spry, C Johnson, H Krawitz, K C Baumann.   

Abstract

BACKGROUND: The role of adjuvant radiation therapy following resection of malignant melanoma involving regional lymph nodes remains controversial. There is no published randomized trial comparing surgery alone to surgery with postoperative radiation therapy that shows a benefit in terms of local control. Some retrospective studies, however, suggest that radiation given postoperatively reduces local recurrence. One of the obstacles to patients routinely being offered radiation therapy is the concern over the added late toxicity that may occur. The present article is a report of the first 130 patients of a prospective phase II multicentre study in Australia and New Zealand.
METHODS: The study was aimed at patients who had had a resection of melanoma in regional nodes or in a regional node basin. The patients were given adjuvant radiation therapy to a recommended dose of 48 Gy in 20 fractions over 4 weeks using accepted radiation techniques for each of the major node sites. This report describes the late toxicity of the treatment received by these patients.
RESULTS: The results of late toxicity experienced in the study were acceptable.
CONCLUSION: The regimen of radiation therapy used could form the basis for the treatment arm of a randomized trial.

Entities:  

Mesh:

Year:  2002        PMID: 12028092     DOI: 10.1046/j.1445-2197.2002.02405.x

Source DB:  PubMed          Journal:  ANZ J Surg        ISSN: 1445-1433            Impact factor:   1.872


  8 in total

Review 1.  Melanoma of the head and neck.

Authors:  Terry A Day; Joshua D Hornig; Anand K Sharma; Frank Brescia; M Boyd Gillespie; Deanne Lathers
Journal:  Curr Treat Options Oncol       Date:  2005-01

2.  The long-term risk of upper-extremity lymphedema is two-fold higher in breast cancer patients than in melanoma patients.

Authors:  Rachel K Voss; Kate D Cromwell; Yi-Ju Chiang; Jane M Armer; Merrick I Ross; Jeffrey E Lee; Jeffrey E Gershenwald; Bob R Stewart; Simona F Shaitelman; Janice N Cormier
Journal:  J Surg Oncol       Date:  2015-10-18       Impact factor: 3.454

3.  Safety and Feasibility of Minimally Invasive Inguinal Lymph Node Dissection in Patients With Melanoma (SAFE-MILND): Report of a Prospective Multi-institutional Trial.

Authors:  James W Jakub; Alicia M Terando; Amod Sarnaik; Charlotte E Ariyan; Mark B Faries; Sabino Zani; Heather B Neuman; Nabil Wasif; Jeffrey M Farma; Bruce J Averbook; Karl Y Bilimoria; Travis E Grotz; Jacob B Jake Allred; Vera J Suman; Mary Sue Brady; Douglas Tyler; Jeffrey D Wayne; Heidi Nelson
Journal:  Ann Surg       Date:  2017-01       Impact factor: 12.969

Review 4.  Recent progress in the treatment and prevention of cancer-related lymphedema.

Authors:  Simona F Shaitelman; Kate D Cromwell; John C Rasmussen; Nicole L Stout; Jane M Armer; Bonnie B Lasinski; Janice N Cormier
Journal:  CA Cancer J Clin       Date:  2014-11-19       Impact factor: 508.702

5.  The influence of postoperative lymph node radiation therapy on overall survival of patients with stage III melanoma, a National Cancer Database analysis.

Authors:  Hasan H Danish; Kirtesh R Patel; Jeffrey M Switchenko; Theresa W Gillespie; Jaymin Jhaveri; Mudit Chowdhary; Mustafa Abugideiri; Keith A Delman; David H Lawson; Mohammad K Khan
Journal:  Melanoma Res       Date:  2016-12       Impact factor: 3.599

6.  Prospective assessment of lymphedema incidence and lymphedema-associated symptoms following lymph node surgery for melanoma.

Authors:  John R Hyngstrom; Yi-Ju Chiang; Kate D Cromwell; Merrick I Ross; Yan Xing; Kristi S Mungovan; Jeffrey E Lee; Jeffrey E Gershenwald; Richard E Royal; Anthony Lucci; Jane M Armer; Janice N Cormier
Journal:  Melanoma Res       Date:  2013-08       Impact factor: 3.599

7.  The Use of ß-Elemene to Enhance Radio Sensitization of A375 Human Melanoma Cells.

Authors:  Zahra Balavandi; Ali Neshasteh-Riz; Fereshteh Koosha; Samira Eynali; Mahmood Hoormand; Minoo Shahidi
Journal:  Cell J       Date:  2019-07-29       Impact factor: 2.479

8.  Synchronous versus sequential chemo-radiotherapy in patients with early stage breast cancer (SECRAB): A randomised, phase III, trial.

Authors:  Indrajit N Fernando; Sarah J Bowden; Kathryn Herring; Cassandra L Brookes; Ikhlaaq Ahmed; Andrea Marshall; Robert Grieve; Mark Churn; David Spooner; Talaat N Latief; Rajiv K Agrawal; Adrian M Brunt; Andrea Stevens; Andrew Goodman; Peter Canney; Jill Bishop; Diana Ritchie; Janet Dunn; Christopher J Poole; Daniel W Rea
Journal:  Radiother Oncol       Date:  2019-11-27       Impact factor: 6.280

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.